Electrical Cardioversion As a Predictor in Postoperative Preservation of Sinus Rhythm
Launched by SAINT PETERSBURG STATE UNIVERSITY, RUSSIA · Oct 21, 2024
Trial Information
Current as of July 26, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying the effects of a treatment called electrical cardioversion on patients with persistent atrial fibrillation (AF) who have undergone a specific heart procedure. The goal is to see if this treatment can help improve heart rhythm in the short and long term after surgery. Researchers will look at how the heart's left atrium changes and whether these changes can help predict if patients will remain free from AF after treatment. Participants will have follow-up exams, including heart scans and monitoring, to track their progress over the next year.
To be eligible for this study, participants should be between 65 and 74 years old and have persistent AF that hasn't responded to medications for at least six months. They also need to have a left atrium size within certain limits. However, individuals with certain heart conditions, previous heart surgeries, or other serious health issues may not qualify. Those who join will receive care, and their experiences will help researchers understand the best ways to treat AF in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Informed consent signed by the patient to participate in the study.
- • Persistent atrial fibrillation resistant to antiarrhythmic drugs for 6 months or more
- • The size of the left atrium is less than 55 mm, volume is less than 130 ml, volume index (LP) is less than 55 ml/m2
- Exclusion Criteria:
- • Reversible causes of atrial fibrillation (hyperthyroidism, pericarditis, myocarditis).
- • Patients in need of myocardial revascularization and/or heart valvular disease correction.
- • Any previous intervention (including MAZE surgery, thoracoscopic ablation; implanted occluder of the auricle of the left atrium.).
- • Patients with severe concomitant pathology requiring correction.
- • Contraindications for administration of anticoagulant therapy.
- • Documented presence of a blood clot in the cavity of the left atrium or other reasons preventing the insertion of catheters into the left atrium.
- • BMI of 40 or more
About Saint Petersburg State University, Russia
Saint Petersburg State University, established in 1724, is a prestigious institution in Russia known for its commitment to academic excellence and research innovation. As a clinical trial sponsor, the university leverages its extensive resources and expertise to advance medical knowledge and improve patient outcomes through rigorous scientific investigation. With a focus on multidisciplinary collaboration, the university fosters partnerships with healthcare professionals, researchers, and industry stakeholders to conduct high-quality clinical trials that adhere to international standards. Its mission is to contribute to the global healthcare landscape by generating reliable data that informs clinical practices and therapeutic interventions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Saint Petersburg, , Russian Federation
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported